NeoGenomics Q3 Revenue Beats Estimates, Company Raises FY2026 Outlook
NeoGenomics reported Q3 revenue above estimates, citing higher-value cancer testing, and raised its FY2026 outlook.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
NeoGenomics Q3 Revenue Beats Estimates, Raises FY2026 Outlook
NeoGenomics said Q3 revenue beat estimates, citing higher-value cancer testing, and raised its FY2026 outlook.